Who is stepping down from their role at Regeneron?

Douglas S. McCorkle, the Vice President, Controller, and Assistant Treasurer, has announced his intention to retire.

When will Mr. McCorkle's retirement take effect?

Mr. McCorkle's retirement is planned for early 2017.

Why is this information important for investors?

This filing is important because it indicates a planned change in senior financial leadership. Mr. McCorkle has been the principal accounting officer since 1998, and his departure will necessitate a succession plan, which investors will want to monitor for continuity and stability in financial reporting.

What is the significance of Mr. McCorkle's role as principal accounting officer?

The principal accounting officer is responsible for overseeing the company's accounting operations and financial reporting. Given Mr. McCorkle's long tenure in this role (since 1998), his departure will create a vacancy in a critical financial position.

REGN 8-K: Leadership Changes

Summary

Regeneron Pharmaceuticals, Inc. filed a Form 8-K on February 19, 2016, to report a significant executive change. Douglas S. McCorkle, the Vice President, Controller, and Assistant Treasurer, announced his intention to retire in early 2017. Mr. McCorkle has held a key financial role as the company's principal accounting officer since 1998. This announcement signals a planned transition in senior financial leadership. Investors will be keenly interested in the succession plan for this critical role, especially given Mr. McCorkle's long tenure and responsibility for accounting. While the retirement is not immediate, it provides Regeneron with ample time to identify and onboard a suitable replacement to ensure continuity and maintain financial integrity.

Key Highlights

1Douglas S. McCorkle, VP, Controller, and Assistant Treasurer, announced his intention to retire in early 2017.
2Mr. McCorkle has served as Regeneron's principal accounting officer since 1998, indicating a long tenure in a key financial role.
3The retirement is planned for early 2017, allowing for a smooth transition.
4The filing is made under Item 5.02 of Form 8-K, pertaining to director and officer changes.
5The company has approximately one year to find and integrate a successor for this position.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Feb 19, 2016)

Summary

Key Highlights

Frequently Asked Questions